OBI Wins " Most Promising Immunotherapy Pipeline" Award
Showcasing TROP2 ADC Research at Biologics World Taiwan

OBI Pharma (4174.TWO) has been recognized as a winner by the Taiwan Biopharma Excellence Awards (TBEA), in the " Most Promising Immunotherapy Pipeline" award category today (3/26). Following OBI-992’s selection as a Top 8 Finalist in last year’s World ADC Awards and the recent recognition at the ADC Asia Congress 2025 in Singapore on 3/12, where it was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award, this new accolade showcases that OBI Pharma’s drug development efforts is not only  in antibody-drug conjugates (ADC) but also in active immunotherapy areas. These consecutive achievements underscore company’s deep talent and expertise in the field of immunotherapy and ADC and OBI’s increasing brand recognition internationally. Specifically, this TBEA award reflected the strong efforts OBI Pharma dedicated to the development of Globo-H active cancer immunotherapy, adagloxad simolenin (OBI-822/OBI-821), and multiple antibody-drug conjugate (ADC) assets.